Ottimo Pharma Strengthens Leadership Team with Senior Appointments
Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development
Appointments support Ottimo Pharma as it rapidly advances the clinical development of lead candidate, Jankistomig, its first-in-class dual pathway, biparatopic IgG1 therapy
IND clearance for Jankistomig is on track for late 2025
[25 February 2025]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo’s preclinical programs and translational strategy, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development, leading Ottimo’s clinical development strategy and execution.
